” Part of the reason in siding with of the decline is legislation direct pharmaceticual joint project to put away up the mass of paracetamol and aspirin pack. A recent examination show that suicides from overdose of paracetamol or aspirin dribble nearly a quarter in the three years then the preface of the [...]
Entries from February 2009
Fingertips turning blue
February 25th, 2009 · No Comments
Tags: Uncategorized
Miracle anti-obesity pill Acomplia rimonabant launched in Europe
February 10th, 2009 · No Comments
Acomplia Rimonabant near Sanofi â Aventis, the much awaited anti-obesity linctus be launch within Europe state-of-the-art week after past two years of clinical trial and try-out on termination of human.
Acomplia, the art dub name of Rimonabant have be industrialized by the French Pharmaceutical giant Sanofi-Aventis to perform by technique of [...]
Tags: Uncategorized
MicardisÃ-based Regimens Help More Patients Achieve Their Blood Pressure Goals
February 8th, 2009 · No Comments
Commenting via the grades, Professor Thomas Unger, Chair of Pharmacology and Director of the Institute of Pharmacology at the CharitÃÂé UniversitÃÂätsmedizin Berlin, said “Controlling patients’ blood hassle be a immoderation with derision that by tradition requests greater than one antihypertensive to transport about optimal normalize. Telmisartan already provide proven powerful blood pressure lower [...]
Tags: Uncategorized
Blood Pressure Drug Telmisartan Shows Powerful Activity Against Stroke Part 3
February 5th, 2009 · No Comments
And in finality, the remedy reduced both the illustriousness of macrophages and MCP-1, and atherosclerosis, in those mice that received transplant of visceral fat. But the pills had no effect in the other mice.
Weill Cornell Medical College Weill Cornell Medical College — Cornell University’s Medical School situated in New York City [...]
Tags: Uncategorized
Clear Evidence for Nifedipine GITS in High Risk Patients with CAD and Hypertension
February 2nd, 2009 · No Comments
The Phase 3 transnational, multi-centre programme catch two efficacy-safety study (SB-767905/012 and SB- 767905/013) and one long-term safety study (SB-767905/014). GSK completed the enrolment sooner than anticipated and the enterprise be target the submission of New Drug Application (NDA) and Marketing Authorisation Application (MAA) filings in mid-2007. The formation of the Phase 3 [...]
Tags: Uncategorized